Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026

NEPHROS INC (NEPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026 Record Second-Quarter Net Revenue Growth of 36% to $6 million; Core Programmatic Revenue Grew by 27% Yea

Original reporting
Published Aug 6, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NEPH
Bullish
medium confidence
Mentioned
$NEPH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NEPHBullishMed
01

Why it matters

Traders can update models for NEPH’s recurring programmatic revenue growth (27% YoY in Q2) and assess earnings quality given the explicit one-time tariff refund and the fact that the cash refund has not yet been received (receivable booked).

02

Market read

A microcap earnings release with record quarterly revenue and improved net income, but with a material one-time tariff refund component and ongoing FX/shipping headwinds.

03

What to watch

Gross margin benefited from the tariff refund but was offset by weaker USD versus Euro, higher shipping expense, and service revenue growth that carries lower gross margins than product sales.

Relevance 7/10Novelty 7/10Timing: after-hours SEC 8-K filed Aug 6, 2026

Background

The company filed an SEC Form 8-K (Item 2.02) with Exhibit 99.1 reporting second-quarter 2026 results and discussing growth drivers and the IEEPA tariff refund.

Company-level read

Ticker impact

$NEPHBullishMedium confidence
Context

Nephros reported Q2 ended June 30, 2026 net revenue of $6.0M (+36% YoY) and $1.2M net income, including a $0.6M tariff refund benefit.

Expected impact

Near-term bias to the upside on the reported growth and profitability, but traders may discount the tariff-refund component and watch for normalization.

Evidence & confidence

This is a primary SEC 8-K earnings release with specific quarterly figures and an explicit one-time IEEPA tariff refund recorded as a reduction of cost of goods sold, plus a booked receivable since the cash refund is not yet received.

Market effects

Water technology and filtration providers may see read-across interest if tariff-related refunds and recurring programmatic revenue trends appear durable.

Limited, company-specific impact centered on a US-listed microcap.

Minimal, though the IEEPA tariff refund and FX-driven cost effects highlight cross-currency and trade-policy sensitivity.

Counterpoint

The headline profitability improvement is partly driven by a one-time tariff refund; underlying gross margin and service mix may be less favorable once the benefit normalizes.

Key entities

  • Nephros, Inc.

    Nasdaq-listed water technology company reporting Q2 2026 financial results and discussing growth and tariff refund effects.

  • IEEPA tariff refund

    Tariffs previously paid under the International Emergency Economic Powers Act were declared invalid; Nephros received approval for a refund and recorded a $0.6M benefit.

  • CBP refund process

    Customs and Border Protection refund process referenced as the mechanism after the Supreme Court decision.

Related articles

$NEPHMed

Nephros (NEPH) Q3 2026 Earnings Call Transcript

Nephros (NEPH) reported Q3 2026 revenue of $5.6M, up 18% YoY, with net income of $500K, up from $300K YoY. Gross margin was 58%, down 3 points due to higher costs. The company added 31 new customer sites, reaching a record 1,766, with healthcare representing 64% of new sites. Nephros highlighted growth in service and education initiatives, aiming to diversify applications beyond healthcare.

$NEPHMed

Nephros Announces Strong Third Quarter 2026 Financial Results

NEPHROS INC (NEPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Strong Third Quarter 2026 Financial Results Year Over Year Net Revenue Growth of 18% and Core Programmatic Revenue Growth of 8% for the Three Months Ended Septem

$IONQMedAI 8/10

IonQ Beat and Raised. Can the Quantum Stock Buck the Tech Selloff?

IonQ reported record revenue of $173.83M, beating estimates and raising FY2026 guidance to $505M-$515M. Despite a 41% YTD stock decline, 24/7 Wall St. set a $35.03 price target (31.5% upside). Analysts' consensus target is $62.27, with concerns over cash burn and dilution. IonQ trades at a lower multiple than peers Rigetti and D-Wave.

$MNRMed

Mach Natural (MNR) Q3 2026 Earnings Call Transcript

Mach Natural (MNR) reported Q3 2026 earnings, highlighting a slowed drilling pace to maintain reinvestment rate below 50% of operating cash flow. The company aims for less than 1x leverage by year-end, projecting 1.4x. Mach distributed nearly $7 to unitholders since 2024, with a 15% yield. Q3 production was 140k boe per day, with total revenues of $360M. Operating cash flow was $165M, and CapEx was $126M. The company plans to increase oil drilling in 2027 while maintaining financial flexibility.